Insulet stock gets a Barclays Hold rating with USD 150 target

Published on 10/08/2026 at 03:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insulet stock carries a USD 150.00 Barclays target dated October 7, 2026. Q2 revenue rose 23.5 percent to USD 801.7 million, while results are due November 4.

Bauhaus-Poster Insulet – geometrisches Primärfarben-Design mit großem MEDIZINTECHNIK-Schriftzug — Insulet Bauhaus-Poster im geometrischen Stil mit MEDIZINTECHNIK-Schriftzug in Primärfarben, ISIN US45784P1012 Healthcare, Illustration mit AI erstellt.

Insulet stock (ISIN US45784P1012) closed at USD 134.73 on Nasdaq on October 6, 2026, as Barclays maintained a Hold rating with a USD 150.00 price target. The latest analyst action keeps attention on valuation while the company prepares its next quarterly update.

Barclays keeps a Hold rating

According to Markets Insider on October 7, 2026, Barclays analyst Matt Miksic maintained Hold and set the target at USD 150.00. That target stands 11.3 percent above the October 6 Nasdaq close, leaving a defined gap between the current quote and the analyst view.

A broader view from MarketScreener on September 24, 2026, showed an Outperform consensus from two analysts and an average target of USD 171.91. The average target was 27.6 percent above the Nasdaq close used in this article.

Q2 revenue reached USD 801.7 million

Insulet reported USD 801.7 million in second-quarter 2026 revenue and USD 95.0 million in net income for the period ended June 30, 2026, according to Markets Insider. Revenue increased from USD 649.1 million in the year-earlier quarter, while net income rose from USD 22.5 million.

The companys second-quarter adjusted EPS was USD 1.66, compared with USD 1.17 a year earlier, a 41.5 percent increase. The earnings call transcript also said Insulet expects 2026 constant-currency revenue growth of 20 to 22 percent, while U.S. Omnipod growth is guided at 17 to 19 percent, reflecting weaker Type 2 retention and utilization trends.

Results date sets the next checkpoint

Insulet announced on October 1, 2026, that it will publish third-quarter 2026 results on November 4, 2026, before the U.S. market opens. Management scheduled the related conference call for 8:00 a.m. ET.

Stock remains near its yearly low

Insulet stock closed at USD 134.73 on Nasdaq on October 6, 2026, versus a 52-week range of USD 126.40 to USD 354.88. Market capitalization was USD 9.3 billion and trading volume was 1,712,370 shares on that quote page, placing the stock 6.6 percent above its yearly low.